New Colorectal Cancer Trials Launch Globally
The fight against colorectal cancer is escalating on multiple fronts. In the U.S., Oncolytics Biotech is launching a new randomized study for its therapy. Meanwhile, Nigeria has begun its first-ever immunotherapy trial for the disease, showing how advanced treatments are expanding into new regions.
Oncolytics Biotech's therapy, pelareorep, is an immunotherapeutic agent that works by selectively infecting and killing cancer cells that have an activated Ras signaling pathway, a common mutation in many cancers. This process, known as oncolysis, releases tumor antigens and viral particles, triggering both the innate and adaptive immune systems to recognize and attack the cancer throughout the body. The new Phase 2 trial will test pelareorep in combination with a standard chemotherapy regimen (FOLFIRI) and bevacizumab in patients with RAS-mutated metastatic colorectal cancer. The Nigerian trial, a collaboration with Memorial Sloan Kettering Cancer Center, marks a significant step for oncology in sub-Saharan Africa. It will test the immunotherapy drug tislelizumab, a PD-1 inhibitor, which works by blocking a protein that cancer cells use to hide from the immune system. This trial specifically targets patients whose tumors have a genetic profile called mismatch-repair deficient (dMMR) or microsatellite instability-high (MSI-H), a subtype that makes up nearly 30% of cases in Nigeria and often responds well to immunotherapy. These trials highlight a major trend in oncology: the shift towards personalized medicine. Bioinformaticians play a crucial role by analyzing large sets of genetic and molecular data from tumors to identify biomarkers, like the RAS or dMMR mutations. This allows clinical teams to stratify patients and match them with the therapies most likely to be effective, moving away from a one-size-fits-all approach. Bringing a new drug through clinical trials involves a diverse team. In a tech-focused role, a computational biologist might model how a drug like pelareorep interacts with the immune system. In a more patient-facing role, a Clinical Research Coordinator (CRC) is central to the trial's execution, managing everything from patient recruitment and scheduling to data collection and ensuring the study follows strict ethical and regulatory guidelines. The educational paths for these careers differ significantly. A medical oncologist, who leads patient care in trials, completes a bachelor's degree, four years of medical school, a three-year internal medicine residency, and a two-to-three-year oncology fellowship. In contrast, a bioinformatics scientist typically pursues a bachelor's degree in a field like biology or computer science, followed by a master's or Ph.D. in bioinformatics or computational biology, focusing on data analysis and programming skills. Globally, colorectal cancer is the third most common cancer and a leading cause of cancer-related death. In 2026, the American Cancer Society projects nearly 159,000 new cases and over 55,000 deaths from the disease in the United States alone. Worryingly, while rates are declining in older adults, they are rising sharply in people under 50, a trend driven by an increase in rectal cancer diagnoses.
